<DOC>
	<DOCNO>NCT01272050</DOCNO>
	<brief_summary>RATIONALE : Radiation therapy use high-energy x-ray kill tumor cell . It yet know radiation therapy regimen effective treat patient relapsed prostate cancer . PURPOSE : This randomized phase III trial study side effect radiation therapy compare two radiation therapy regimens treat patient relapsed prostate cancer surgery .</brief_summary>
	<brief_title>Radiation Therapy Treating Patients With Relapsed Prostate Cancer After Surgery</brief_title>
	<detailed_description>OBJECTIVES : - To determine tumor control patient biochemically relapsed prostate cancer without macroscopic disease treat dose-intensive salvage radiotherapy . - To determine toxicity patient . - To determine quality life patient . OUTLINE : This multicenter study . Patients stratify accord Gleason score ( ≥ 8 v 7 v ≤ 6 ) , pathological tumor classification ( pT3b v others ) , lymphadenectomy perform ( yes [ pN0 ] v [ cN0 ] ) , persistent PSA prostatectomy ( detectable [ ≥ 0.1 ng/mL ] v undetectable [ &lt; 0.1 ng/mL ] ) , PSA randomization ( &gt; 0.5 ng/mL v ≤ 0.5 ng/mL ) , participate center , radiotherapy technique ( 3-dimensional conformal radiation therapy [ 3D-CRT ] v intensity-modulated radiation therapy [ IMRT ] /rotational technique ) . Patient randomize 1 2 treatment arm . - Arm A : Beginning least 12 week surgery , patient undergo radiotherapy* day , 5 day week , 6.4 week total dose 64 Gy ( 32 fraction 2 Gy 6.4 week ) . - Arm B : Patients undergo radiotherapy* day , 5 day week , 7 week total dose 70 Gy ( 35 fraction 2 Gy 7 week ) . NOTE : *3-dimensional conformal radiation therapy , rotational technique Tomotherapy® , Rapidarc® , intensity-modulated arc technique volumetric-modulated arc therapy eligible . Patients complete quality-of-life questionnaire baseline 3 , 12 , 24 , 36 , 48 , 60 month complete study therapy . After completion study treatment , patient follow every 6 month 3 year every 12 month 10 year .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis adenocarcinoma prostate Lymph node negative disease Stage pT2a3b ; R01 ; pN0 cN0 Undergone radical prostatectomy ≥ 12 week prior randomization PSA progression prostatectomy define two consecutive rise second rise value &gt; 0.1 ng/mL OR three consecutive rise ( first value must measure 4 week radical prostatectomy ) PSA ≤ 2 ng/mL randomization No persistent PSA &gt; 0.4 ng/mL , 420 week radical prostatectomy No palpable prostatic fossa mass suggestive recurrence , unless ultrasoundguided biopsy nonmalignant No presalvage radiotherapy pelvic lymph node enlargement &gt; 1 cm short axis diameter abdomen pelvis ( cN1 ) ( unless enlarge lymph node sample negative ) No evidence macroscopic local recurrence metastatic disease presalvage radiotherapy MRI ( IV contrast ) multislice compute tomography ( IV oral contrast ) abdomen pelvis assess within 16 week prior randomization No presence history bone metastasis ( bone scan must perform case clinical suspicion [ e.g. , bone pain ] ) Gleason score must available PATIENT CHARACTERISTICS : WHO performance status 01 Fertile patient must use effective contraception 6 month completion study therapy Compliant geographically proximal allow proper stag followup No prior invasive malignancy , except nonmelanomatous skin cancer malignancy document diseasefree survival ≥ 5 year No bilateral hip prosthesis No severe active comorbidity likely impact advisability doseintensive salvage radiotherapy , include follow : History inflammatory bowel disease Acute bacterial fungal infection require intravenous antibiotic time randomization Unstable angina and/or congestive heart failure require hospitalization within past 6 month Transmural myocardial infarction within past 6 month Chronic obstructive pulmonary disease exacerbation respiratory illness require hospitalization preclude study therapy time randomization No psychiatric disorder preclude understanding information trialrelated topic , give informed consent , fill qualityoflife questionnaire PRIOR CONCURRENT THERAPY : See Disease Characteristics No prior pelvic radiotherapy No hormonal treatment bilateral orchiectomy prior follow prostatectomy At least 4 week since prior concurrent use product know affect PSA level ( e.g. , PC Calm , PC Plus , PC SPES , finasteride , fluconazole ) At least 30 day since prior treatment another clinical trial No concurrent anticancer treatment , include luteinizing hormonereleasing hormone ( LHRH ) analogue , antiandrogens , orchiectomy , chemotherapy No concurrent investigational experimental treatment drug INCLUSION CRITERIA Patient must give write informed consent randomization . Lymph node negative adenocarcinoma prostate treat radical prostatectomy least 12 week randomization . Tumor stage pT2a3b , R01 , pN0 cN0 accord UICC TNM 2009 ( see Appendix 1 ) , Gleason score available . PSA progression prostatectomy define two consecutive rise final PSA &gt; 0.1 ng/mL three consecutive rise . The first value must measure early 4 week radical prostatectomy . PSA randomization ≤ 2 ng/mL . WHO performance status 01 randomization . Age randomization 18 75 year . Baseline QoL questionnaire ( QLQ ) complete . Patient agree father child salvage RT 6 month thereafter . Patient compliance geographic proximity allow proper stag followup . The responsible pathologist agree provide sample material central pathological review ( see Section 16 ) tissue banking ( patient give inform consent ) within specify timeline . EXCLUSION CRITERIA Persistent PSA 420 week radical prostatectomy &gt; 0.4 ng/mL Palpable prostatic fossa mass suggestive recurrence , unless ultrasound guide biopsy nonmalignant . Presalvage RT pelvic lymph node enlargement &gt; 1 cm short axis diameter abdomen pelvis ( cN1 ) , unless enlarge lymph node sample negative , and/or evidence macroscopic local recurrence metastatic disease presalvage RT MRI ( magnetic resonance imaging ; i.v . contrast ) multislice compute tomography ( CT ; i.v . oral contrast ) abdomen pelvis assess within 16 week prior randomization . Presence history bone metastasis . Bone scan must perform case clinical suspicion ( e.g . bone pain ) . Prior invasive malignancy , except nonmelanomatous skin cancer malignancy document diseasefree survival minimum 5 year . Hormonal treatment bilateral orchiectomy prior follow prostatectomy . Bilateral hip prosthesis . Prior pelvic radiotherapy . The use product know affect PSA level within 4 week prior start trial treatment ( e.g . PC Calm , PC Plus , PC SPES , finasteride , fluconazole ) . Severe active comorbidity likely impact advisability dose intensified salvage RT . Psychiatric disorder preclude understanding information trial related topic , give informed consent fill QoL questionnaire . Concurrent treatment experimental drug anticancer therapy , treatment clinical trial within 30 day prior trial entry .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>adenocarcinoma prostate</keyword>
	<keyword>recurrent prostate cancer</keyword>
	<keyword>stage IIA prostate cancer</keyword>
	<keyword>stage IIB prostate cancer</keyword>
	<keyword>stage III prostate cancer</keyword>
</DOC>